Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by FredTheVoiceon Sep 27, 2019 8:00am
165 Views
Post# 30169754

RE:RE:RE:one catalyst down

RE:RE:RE:one catalyst downI respect you posters and it is widely spread out as opinion that European approval is just a tag on a shirt.

Not for me. Its huge and the turning point that the market and investors, in a couple of months, looking at the chart, will pin as the MOMENT.

Its simple, first, it proves that managing team is on line with their milestone and that new money and oppotunity will be coming from EUROPE, and the window is now opened with EUROPE for EGRIFTA/NASH. THERA is a company making business in EUROPE. And who knows, TROGARZO could bring surprises in EUROPE, with better sales than anticipated. Some here mentionned a good point: it could in the short term boost the US sales. Thats important. Thats all confidence. CONFIDENCE is what TANGUAY and THERA needs and GOT.

Im hoping very soon for that GRINSPOON publication.........that will be important as well.

But I think we are under-estimating the EUROPE factor. And the share price will reflect or not my point of vue at the end of octobre or sooner. Lets say 8$C per share is were I see THERA at the end of october. And that would mean that the EUROPE FACTORS was important.

Have a great day (And JFM, dont you love when PALINC just rushes to respond to your post ? He has something about you.......)

FTV.


Bullboard Posts